US Patent

US8039479 — Compounds and compositions as protein kinase inhibitors

Composition of Matter · Assigned to IRM LLC · Expires 2030-06-29 · 4y remaining

Vulnerability score 10/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects novel pyrimidine and pyridine derivatives that can be used as protein kinase inhibitors.

USPTO Abstract

The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.

Drugs covered by this patent

Patent Metadata

Patent number
US8039479
Jurisdiction
US
Classification
Composition of Matter
Expires
2030-06-29
Drug substance claim
Yes
Drug product claim
Yes
Assignee
IRM LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.